An Analysis of Pharmaceutical Lending by the World Bank

Vista sencilla de ítem
dc.creatorRodríguez-Monguió, Rosa
dc.creatorRovira, Juan
dc.date2013-05-30T20:57:16Z
dc.date2013-05-30T20:57:16Z
dc.date2004-09
dc.date.accessioned2026-07-01T01:12:20Z
dc.descriptionThe World Bank (WB) began to lend for health, nutrition, and population (HNP) in the late 1970s. Today, the Bank has become the single largest external source of HNP financing in low- and middle-income countries. The Bank's activities in the HNP sector are based on the rationale that investments in health, nutrition, and population constitute an investment in human capital that is necessary for enhanced welfare, reduced poverty and sustainable growth. During fiscal years (FY) 1999 to 2002, the World Bank approved 683 lending projects in all sectors, with a total lending amount of US$ 38,306 million (2001 prices). During the same period of time, the World Bank approved 65 HNP lending projects, with a total cumulative value of US$ 3,298 million (2001 prices). The Bank has been financing pharmaceutical activities within the HNP portfolio since 1983. In total, the Bank has provided financing for pharmaceuticals in over 100 HNP projects in all six regions. According to the results of the present research, contracts for the procurement of pharmaceuticals and medical products (PMP) under Bank financed projects from FY 1999 to FY 2002 accounted for almost 36 percent of the procurement of goods in HNP, and for 18 percent of the total HNP procurement activity including goods, civil works, consulting and other services. Despite the increased interest in pharmaceuticals, lending in this area has been conducted without the guidance of an explicit operational policy on pharmaceuticals. While the World Bank has produced a number of policy papers and reports on pharmaceuticals, these are not considered operational policy. In this situation, good practices and implicit policy guide the pharmaceutical activities of the HNP sector and the Bank's pharmaceutical activities.
dc.formatapplication/pdf
dc.formattext/plain
dc.identifierhttp://documents.worldbank.org/curated/en/2004/09/5621115/analysis-pharmaceutical-lending-world-bank
dc.identifierhttps://hdl.handle.net/10986/13730
dc.identifierhttps://doi.org/10.1596/13730
dc.identifier.urihttp://hdl.handle.net/123456789/416094
dc.languageEnglish
dc.languageen_US
dc.publisherWorld Bank, Washington, DC
dc.relationHealth, Nutrition and Population (HNP) discussion paper;
dc.rightsCC BY 3.0 IGO
dc.rightshttp://creativecommons.org/licenses/by/3.0/igo/
dc.rightsWorld Bank
dc.subjectANTIBIOTICS
dc.subjectAPPRAISAL REPORTS
dc.subjectBORROWER
dc.subjectCOMPETITIVE BIDDING
dc.subjectCONCESSIONAL LOANS
dc.subjectCONTRACEPTIVES
dc.subjectCOST ACCOUNTING
dc.subjectDEVELOPMENT GOALS
dc.subjectDRUGS
dc.subjectECONOMICS
dc.subjectEXPENDITURES
dc.subjectFISCAL YEAR
dc.subjectFOREIGN EXCHANGE
dc.subjectHEALTH CARE
dc.subjectHEALTH SECTOR
dc.subjectHEALTH SERVICES
dc.subjectHOSPITALS
dc.subjectHUMAN CAPITAL
dc.subjectINCOME
dc.subjectLEGISLATION
dc.subjectLENDING DOCUMENTS
dc.subjectLENDING INSTRUMENTS
dc.subjectLENDING OPERATIONS
dc.subjectLOAN
dc.subjectLOAN AGREEMENTS
dc.subjectMEDICAL SUPPLIES
dc.subjectMEDICINE
dc.subjectNUTRITION
dc.subjectPHARMACEUTICAL PRODUCTS
dc.subjectPHARMACEUTICAL SECTOR
dc.subjectPHARMACEUTICAL SUPPLIERS
dc.subjectPHARMACEUTICALS
dc.subjectPRIVATE SECTOR
dc.subjectPROCUREMENT
dc.subjectPROJECT IMPLEMENTATION
dc.subjectPUBLIC HEALTH
dc.subjectPUBLIC POLICIES
dc.subjectPURCHASING
dc.subjectRATIONAL USE OF DRUGS
dc.subjectSANITATION
dc.subjectSUPPLIERS
dc.subjectTECHNICAL ASSISTANCE
dc.subjectTRANSPARENCY
dc.subjectTRUST FUNDS
dc.subjectVACCINES
dc.subjectVENEZUELA
dc.subjectWATER SUPPLY
dc.subjectLENDING
dc.subjectLENDING OPERATIONS
dc.titleAn Analysis of Pharmaceutical Lending by the World Bank

Archivos

Colecciones

AgroKnow